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Background: Diabetes mellitus has worse outcome after percutaneous coronary inter-
vention. Aim: We assessed stent thrombosis (ST), major adverse cardiac events
(MACE), and major bleeding rates at 1 year after implantation of sirolimus-eluting
stents (SES) in patients with diabetes mellitus in a large multicenter registry. Methods:
From May 2006 to April 2008, 15,147 unselected consecutive patients were enrolled at
320 centers in 56 countries in a prospective, observational registry after implantation
of1 SES. Source data were verified in 20% randomly chosen patients at> 100 sites.
Adverse events were adjudicated by an independent Clinical Event Committee.
Results: Complete follow-up at 1 year was obtained in 13,693 (92%) patients, 4,577
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(30%) of whom were diabetics. Within diabetics, 1,238 (9%) were insulin-treated dia-
betics (ITD). Diabetics were older (64 vs. 62 years, P< 0.001), with higher incidence of
major coronary risk factors, co-morbidities, and triple-vessel coronary artery disease.
Coronary lesions had smaller reference vessel diameter (2.886 0.46 vs. 2.936 0.45 mm,
P< 0.001) and were more often heavily calcified (26.1% vs. 22.6%, P< 0.001). At 1 year,
diabetics had higher MACE rate (6.8% vs. 3.9%, P< 0.001) driven by ITD (10.6% vs.
5.5%, P<0.001). Finally, diabetics had significant increase in ST (1.7% vs. 0.7%,
P< 0.001), principally owing to ITD (3.4% vs. 1.1%, P<0.001). There was an overall low
risk of major bleeding during follow-up, without significant difference among sub-
groups. Conclusions: In the e-SELECT registry, diabetics represented 30% of patients
undergoing SES implantation and had significantly more co-morbidities and complex
coronary lesions. Although 1-year follow-up documented good overall outcome in dia-
betics, higher ST and MACE rates were observed, mainly driven by ITD. VC 2015 Wiley
Periodicals, Inc.
Key words: percutaneous coronary intervention; sirolimus-eluting stent; diabetes melli-
tus; stent thrombosis; antithrombotic therapy; bleeding complications
INTRODUCTION
Despite the markedly lower incidence of restenosis
associated with drug-eluting stents (DES) as compared
with bare-metal stents in patients with diabetes melli-
tus (DM) after percutaneous coronary intervention
(PCI), the more complex coronary anatomy, prothrom-
botic and inflammatory state, and associated cardiovas-
cular risk factors of diabetics remain independent
predictors of unfavorable clinical outcomes [1].
Although insulin-treated DM is associated with high
target lesion revascularization (TLR) rates after bare-
metal stent implantation [2] and is an independent pre-
dictor of stent thrombosis (ST) [3], the impact of non–
insulin-treated vs. insulin-treated DM on DES resteno-
sis is less clear. Moreover, the analysis of interaction
between different baseline cardiovascular risk profiles
and prolonged dual antiplatelet therapy (DAPT) with
the ongoing risk of ST, recurrent ischemia, and bleed-
ing after DES use in routine interventional practice is
still a debated problem and a challenging task, requir-
ing large, unselected populations of diabetic patients
with sufficient follow-up.
The e-SELECT registry is a large, multicenter, inter-
national clinical registry of “all-comer” patients with
coronary artery disease undergoing PCI with the
Cypher sirolimus-eluting stent (SES) [3]. This report
presents the findings in the diabetic patient group en-
rolled in the e-SELECT registry, evaluating the inter-
action between baseline DM treatment (insulin use vs.
no insulin) and outcome. Although first-generation
SES have been replaced by newer stent designs eluting
different antiproliferative drugs, a relatively large num-
ber of second-generation DES are still coated with
sirolimus and are currently used in patients with DM
[4]. Accordingly, the e-SELECT registry data may
serve as a clinical benchmark for future comparative
effectiveness analyses and may improve our clinical
understanding of PCI long-term results in the DM
population.
METHODS
The details of the e-SELECT registry, which en-
rolled 15,147 patients at 320 medical centers in 56
countries, have been published elsewhere [3]. In brief,
baseline data were collected electronically at each par-
ticipating center between May 2006 and April 2008 in
consecutive, eligible patients who underwent implanta-
tion of 1 Cypher SelectVR or Cypher Select PlusVR
SES (Cordis Corp., Bridgewater, NJ) according to
standard clinical practices and procedural techniques.
The data included demographic information, cardiovas-
cular history, co-morbidities, operator-defined lesion
characteristics, procedural details, and antithrombotic
regimen [5]. Patients were followed-up at 30, 180, and
360 days by telephone, office visit, or by contact with
primary physicians or referring cardiologists. Data
were transferred to an independent data management
organization, analyzed by an independent Clinical
Event Committee, and monitored for accuracy by an
independent organization in 20% of the overall sample.
End Points and Supervision of the e-SELECT
Registry
The primary end point of the registry was a composite
of definite and probable ST at 1 year of follow-up, as
defined by the Academic Research Consortium [6]. The
secondary end points at 1 year included major bleeding
according to the Safety and Efficacy of Intravenous
Enoxaparin in Elective Percutaneous Coronary Inter-
vention: An International Randomized Evaluation defi-
nition [7], cardiac and noncardiac death, myocardial
infarction (MI), and major adverse cardiac events
(MACE) defined as death from any cause, MI, and TLR.
2 Bartorelli et al.
Catheterization and Cardiovascular Interventions DOI 10.1002/ccd.
Published on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).
A Steering Committee planned the analysis, presenta-
tions, and publications of the e-SELECT results. The
algorithms used to classify clinical events and the criteria
used for MACE adjudication were developed by a Clini-
cal Event Committee composed of interventional cardiol-
ogists who were not associated with the sponsor and were
not participants in the registry [3]. The Committee also
adjudicated all MACE, deaths, ST, and major bleeding.
Statistical Analysis
For all patients, standard descriptive statistics were
used for baseline lesion and procedural characteristics
and for clinical results. Continuous variables are pre-
sented as means standard deviations, medians, and
ranges and were compared among groups using t-test
or Wilcoxon rank–sum test as appropriate. Categorical
variables are presented as numbers and percentages
and were compared using v2 test or Fisher’s exact test
as appropriate. Cumulative rates of adverse clinical
events were calculated using event-specific adjusted
denominators. Kaplan–Meier curves and time-to-event
summaries were constructed to examine the long-term
incidence of clinical and safety end points. Univariable
and multivariable Cox proportional hazard regression
models were used to compare time-dependent dichoto-
mous events among groups. Missing values were not
imputed. All statistical analyses were performed with
the SAS software, version 9.1 or higher (SAS Institute,
Cary, NC). A P-value <0.05 was considered signifi-
cant. All tests were two sided.
RESULTS
Registry Sample
The e-SELECT registry comprised 15,147 patients
who fulfilled the inclusion and exclusion criteria speci-
fied in the protocol. Follow-up data were available in
14,905 patients at 30 days, 14,430 at 6 months, and
13,693 at 1 year, representing 99%, 96%, and 92% of
survivors, respectively. In this analysis, 10,506 (70%)
patients with 13,833 lesions were nondiabetics (ND),
whereas 4,577 (30%) patients with 6,091 lesions had
DM. Within the DM group, 1,238 (9%) patients with
TABLE I. Baseline Characteristics of Insulin-Treated and Non–Insulin-Treated Diabetics Vs. Nondiabetics
Diabetics
Nondiabetics
(n¼ 10,506 patients) P*
Insulin-treated
(n¼ 1,238 patients)
Non–insulin-treated
(n¼ 3,339 patients)
Age, years 63.4 9.9 63.7 10.1 61.5 11.1 <0.001
Men 768 (62.0) 2,475 (74.1) 8,130 (77.4) <0.001
Body mass index 30 471 (38.0) 1,062 (31.9) 2,140 (20.4) <0.001
History of:
Myocardial infarction 487 (39.3) 1,074 (32.2) 3,293 (31.3) <0.001
Percutaneous coronary intervention 449 (36.3) 1,055 (31.6) 3,346 (31.8) ns
Coronary artery bypass grafting surgery 164 (13.2) 351 (10.5) 855 (8.1) <0.001
Hypertension 981 (79.2) 2,589 (77.5) 6,601 (62.8) <0.001
Hyperlipidemia 921 (74.4) 2,461 (73.7) 6,907 (65.7) <0.001
Current smoking 170 (13.7) 529 (15.8) 2,331 (22.2) <0.001
Peripheral vascular disease 171 (13.8) 255 (7.6) 515 (4.9) <0.001
Cerebral vascular accident 99 (8.0) 190 (5.7) 354 (3.4) <0.001
Serum creatinine> 177 mmol/L 99 (9.0) 69 (2.3) 172 (1.9) <0.001
Chronic obstructive lung disease 76 (6.1) 147 (4.4) 374 (3.6) <0.001
Mean Charlson index score 2.7 1.8 1.9 1.2 0.6 0.9 <0.001
Charlson index score 3 532 (43.0) 640 (19.2) 374 (3.6) <0.001
Preprocedural AVK therapy 33 (2.7) 64 (1.9) 199 (1.9) ns
Indications for index procedure
Stable angina 491 (39.7) 1,328 (39.8) 4,487 (42.7) <0.001
Unstable angina 332 (26.8) 889 (26.6) 2,699 (25.7) ns
Myocardial infarction 219 (17.7) 598 (17.9) 1,926 (18.3) ns
Silent ischemia/others 196 (15.8) 524 (15.7) 1,394 (13.3) <0.001
Triple vessel coronary artery disease 309 (25.0) 668 (20.0) 1,640 (15.6) <0.001
Target vessel
Left anterior descending artery 746 (47.1) 2,127 (49.1) 7,074 (52.1) <0.001
Circumflex artery 373 (23.5) 1,056 (24.4) 2,853 (21.0) <0.001
Right coronary artery 437 (27.6) 1,113 (25.7) 3,509 (25.8) ns
Saphenous vein graft 33 (2.0) 103 (2.3) 178 (1.3) <0.001
Values are meanSD or number (%) of observations.
*All diabetics vs. nondiabetics.
AVK, antivitamin K.
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1,633 lesions were insulin-treated diabetics (ITD). In
the ITD subgroup, 244 (20%) patients were classified
as type 1 DM, but the great majority presented a diag-
nosis of type 2 DM. The clinical characteristics of the
three groups are shown in Table I. The DM group was
characterized by fewer males, but a higher prevalence
of obesity, other major coronary risk factors, co-
morbidities, and triple-vessel coronary artery disease
compared with ND patients. A greater proportion of di-
abetic patients had a Charlson index score 3.
Lesion and Procedural Characteristics
The lesion and procedural characteristics of the three
patient groups are shown in Table II. Target vessels in
diabetics were smaller and were more likely to be
moderately to heavily calcified, but less likely to have
bifurcation involvement. Albeit statistically significant,
the differences in reference vessel diameter and prepro-
cedural percent vessel stenosis between diabetics and
ND were small.
Diabetic patients were less likely to undergo direct
stenting and postdilation; however, they were treated
with higher maximal balloon dilation pressures. They
also were less likely to undergo intravascular ultra-
sound assessment.
Antithrombotic and Antiplatelet Therapy
Table III shows the number of patients treated with
thienopyridine, aspirin, or both at 1, 6, and 12 months.
At 30-day follow-up, 97.6% of all DM patients were
TABLE II. Lesion and Procedure Characteristics of Insulin-Treated Diabetics, Non–Insulin-Treated Diabetics and Nondiabetics
Diabetics
Nondiabetics
(n¼ 10,506 patients;
13,833 lesions) P*
Insulin-treated
(n¼ 1,238 patients;
1,606 lesions)
Non–insulin-treated
(n¼ 3,339 patients;
4,385 lesions)
Reference vessel diameter, mma 2.85 0.45 2.89 0.47 2.93 0.45 <0.001
Preprocedural percent stenosisa 84.05 11.28 84.13 12.30 84.70 12.46 0.002
Lesion length, mma 20.53 11.39 19.94 11.25 20.29 11.72 ns
Lesion subsets
Restenoticb 194 (12.0) 500 (11.4) 1,618 (11.9) ns
In-stent restenosisb 179 (11.1) 469 (10.7) 1,531 (11.2) ns
Length 30 mm 161 (13.2) 428 (13.0) 1,422 (13.7) ns
Bifurcationb 207 (12.9) 582 (13.3) 2,039 (15.0) <0.001
Chronic total occlusionb 51 (3.2) 114 (2.6) 452 (3.3) 0.04
Reference vessel diameter< 2.25 mm 60 (4.9) 163 (4.9) 361 (3.5) <0.001
Ostial 203 (12.6) 516 (11.8) 1,753 (12.9) ns
Moderately or severely calcifiedb 447 (30.0) 988 (24.7) 2,766 (22.6) <0.001
Procedural characteristics
Numbers per patient
Vessels treated 1.18 0.42 1.19 0.42 1.17 0.42 0.07
Lesions treated 1.32 0.62 1.34 0.61 1.32 0.62 ns
Stents implanted 1.54 0.88 1.56 0.84 1.55 0.87 ns
Overlapping stents 161 (13.0) 479 (14.3) 1,576 (15.0) ns
Total stent length, mm
Per lesion 25.5 13.1 25.0 13.0 25.4 13.3 ns
Per patient 33.4 21.7 33.3 20.5 33.5 21.0 ns
Direct stenting 550 (34.2) 1,509 (34.4) 4,937 (36.2) 0.01
Post-dilatation 606 (33.7) 1,718 (34.5) 5,720 (36.9) <0.001
Maximal pressure, atm 17.6 4.3 17.2 4.2 17.0 4.3 <0.001
Intravascular ultrasound imaging 44 (2.8) 132 (3.1) 537 (4.0) <0.001
Antithrombotic regimen
Preprocedural
Aspirin 1,060 (87.4) 2,867 (87.3) 8,796 (85.1) <0.001
Clopidogrel 766 (63.1) 1,938 (59.1) 6,253 (60.5) ns
Ticlopidine 23 (1.9) 68 (2.1) 190 (1.8) ns
Intraprocedural
Glycoprotein IIb/IIIa inhibitor 204 (16.7) 497 (15.0) 1,652 (15.8) ns
Bivalirudin 40 (3.3) 87 (2.6) 346 (3.3) ns
Unfractionated/low-molecular-weight heparin 1,108 (90.7) 2,908 (87.7) 9,179 (87.9) ns
Values are meanSD, or number (%) of observations.
aVisual estimate.
bThe denominator is the group-specific number of lesions.
*All diabetics vs. nondiabetics.
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treated with DAPT (clopidogrel or ticlopidineþ aspirin),
vs. 98.2% of ND (P¼ 0.02). Reasons for 30-day inter-
ruption of DAPT included bleeding, switching to antago-
nist of vitamin-K, allergy or intolerance, and emergent
surgery. At 1 year, 81% of all diabetic patients received
DAPT vs. 78.7% of ND (P¼ 0.002).
Stent Thrombosis, Major Bleeding, and Other
MACE
The 30-, 180- and 360-day rates of MACE are pre-
sented in Table IV. Multivariable prediction analysis
for MACE is reported in Table I (Supporting Informa-
tion Appendix). Fig. 1A shows the cumulative inci-
dence of ST in ITD, non–insulin-treated diabetics
(NITD), and in ND. A considerably higher incidence
of definite and probable ST was observed in ITD vs.
the two other groups, and, at 12 months, the difference
was statistically significant (P< 0.001) even after
adjusting for baseline differences among groups (Table
V). In contrast, the 1-year cumulative ST rates in the
NITD subgroup and ND were similarly very low. The
relationship between DAPT compliance and the inci-
dence of early and late definite and probable ST in
TABLE III. Antithrombotic Regimen Compliance in Nondiabetics and the Two Diabetic Subgroups at 30, 180, and 360 Days of
Follow-up
Diabetics
Antiplatelet therapy Insulin-treated Non–insulin-treated Nondiabetics P*
30 days n¼ 1,168 n¼ 3,168 n¼ 10,506
Dual 1,138 (97.4) 3,093 (97.6) 9,822 (98.2) 0.02
Single 20 (1.7) 58 (1.8) 152 (1.5) ns
None 8 (0.7) 7 (0.2) 14 (0.1) 0.02
180 days n¼ 1,110 n¼ 3,055 n¼ 9,634
Dual 1,047 (94.3) 2,890 (94.6) 9,123 (94.7) ns
Single 55 (5.0) 146 (4.8) 457 (4.7) ns
None 7 (0.6) 17 (0.6) 51 (0.5) ns
360 days n¼ 1,072 n¼ 2,974 n¼ 9,479
Dual 853 (79.6) 2,425 (81.5) 7,460 (78.7) 0.002
Single 199 (18.6) 510 (17.1) 1,906 (20.1) <0.001
None 19 (1.8) 35 (1.2) 110 (1.2) ns
Values are number (%) of observations. Of the patients treated with a thienopyridine, 98.6% received clopidogrel and 1.4% received ticlopidine.
*All diabetics vs. nondiabetics.
TABLE IV. Cumulative Rates of Adverse Clinical Events at 1-Year Follow-up
Diabetics
Nondiabetics
(n¼ 10,506 patients) P*
Insulin-treated
(n¼ 1,238 patients)
Non–insulin-treated
(n¼ 3,339 patients)
Deaths
From all causes 54 (4.8) 62 (2.0) 120 (1.2) <0.001
Cardiac 41 (3.7) 40 (1.3) 55 (0.6) <0.001
Myocardial infarction 54 (4.9) 57 (1.9) 153 (1.6) <0.001
Q-wave 8 (0.7) 10 (0.3) 39 (0.4) 0.8
Non-Q-wave 45 (4.1) 48 (1.6) 115 (1.2) <0.001
TLR 51 (4.7) 79 (2.6) 179 (1.9) <0.001
PCI 45 (4.1) 73 (2.4) 162 (1.7) <0.001
CABG 6 (0.6) 9 (0.3) 22 (0.2) 0.2
MACE 120 (10.6) 167 (5.5) 384 (4.0) <0.001
Stent thrombosis
0–30 days 22 (1.8) 25 (0.8) 40 (0.4) <0.001
31-360 days 15 (1.4) 8 (0.3) 25 (0.3) 0.01
Total 37 (3.4) 33 (1.1) 65 (0.7) <0.001
Major bleeding
0–30 days 5 (0.4) 15 (0.5) 37 (0.4) 0.5
31-360 days 10 (1.0) 18 (0.6) 46 (0.5) 0.1
Total 15 (1.4) 33 (1.1) 83 (0.9) 0.1
Values are number (%) of observations.
*All diabetics vs. nondiabetics.
PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting.
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diabetics and ND is shown in Fig. 2. The great major-
ity of ST occurred during DAPT treatment in all
groups (Fig. 2). In ITD fully compliant with DAPT,
we observed a sixfold higher risk of ST compared with
ND throughout the first year. Similarly, NITD demon-
strated a higher risk of ST during the first 30 days
compared with ND (0.7% vs. 0.3%, P¼ 0.003), but,
beyond the first month, no significant difference in ST
risk was observed between these two groups. The risk
of ST after discontinuing one or both antiplatelet
agents within 30 days after the index procedure was
high for both diabetics and ND (3.4% and 5.3%,
respectively), as shown in Table VI. The risk of ST in
patients deviating from DAPT decreased rapidly
beyond the first month, with an ST rate equivalent to
that observed in patients fully compliant with DAPT.
As seen in Table VII, ST was, to a higher degree, asso-
ciated with MI in ND compared with ITD and NITD
(77%, 65%, and 51%, respectively). However, ST was
more often associated with fatal outcomes in ITD and
NITD compared with ND (43%, 42%, and 25%,
respectively).
Fig. 1. Kaplan–Meier curves showing cumulative incidence
of (A) stent thrombosis and (B) major bleeding complications
up to 1 year in insulin-treated diabetics, non–insulin-treated
diabetics and nondiabetic patients.
TABLE V. Multivariable Predictor Analysis for Index PCI-Related ARC Stent Thrombosisa Within 0–360 Days
Variable Coefficient Standard error Hazard ratio (95% CI) P-value
Charlson comorbidity index 0.29 0.05 1.3 (1.2–1.5) <0.001
Previous CABG 0.99 0.24 2.7 (1.7–4.3) <0.001
ITDM 0.97 0.26 2.6 (1.6–4.4) <0.001
Multivessel disease (two- or three-vessel disease or significant LMS) 0.60 0.23 1.8 (1.2–2.9) 0.010
ACS 0.55 0.22 1.7 (1.1–2.7) 0.014
Preprocedure Hb (by 10 g/L decrement) 0.12 0.05 1.1 (1.0–1.2) 0.015
Platelet function tested 0.61 0.26 1.8 (1.1–3.1) 0.021
Any deviation from continuous DAPT (up to 1 month FU visit) 0.77 0.37 2.2 (1.0–4.5) 0.040
Maximal lesion length (by 10 mm incrementb) 0.14 0.07 1.1 (1.0–1.3) 0.040
Diabetes with retinopathy, neuropathy, or nephropathy 0.70 0.37 0.5 (0.2–1.0) 0.06
History of hyperlipidemia 0.33 0.21 0.7 (0.5–1.1) 0.12
AMI (72 hrs) as indication for PCI 0.42 0.27 1.5 (0.9–2.6) 0.12
Age (by 10 year incrementb) 0.10 0.10 1.1 (0.9–1.3) 0.35
aStent thrombosis events related to stents implanted at index procedure.
bHazard ratio is per increase of 10; for Charlson comorbidity index, hazard ratio is per increase of 1.
PCI, percutaneous coronary intervention; ARC, Academic Research Consortium; CABG, coronary artery bypass grafting; ITDM, insulin-treated dia-
betes mellitus; LMS, left main stenosis; ACS, acute coronary syndromes; DAPT, dual antiplatelet therapy; FU, follow-up; AMI, acute myocardial
infarction.
Fig. 2. Early and late stent thrombosis rates in insulin-
treated diabetics, non–insulin-treated diabetics, and nondia-
betic patients compliant with dual antiplatelet therapy.
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As reported in Table IV and depicted in Fig. 1B,
there was an overall low risk of major bleeding during
follow-up, and no significant difference in the type of
major bleeding events among the three groups (Fig. 1,
Supporting Information Appendix). The freedom from
major bleeding was not different comparing ITD
(1.4%), NITD (1.1%), and ND (0.9%), with a log-rank
P-value of 0.1. Multivariable analysis failed to prove
that DM was an independent predictor of major bleed-
ing during follow-up (Table II, Supporting Information
Appendix). Moreover, none of the DM patients who
experienced ST within 1 year had a major bleeding
event (Table VII).
DISCUSSION
The e-SELECT registry collected longitudinal out-
come data of the largest, unselected (“real-world”),
consecutive cohort of patients treated with SES implan-
tation (Cypher SelectVR or Cypher Select PlusVR ). This
report summarizes pertinent performance data in the
DM group, assessing differential outcome in ITD and
NITD subgroups. Patients with DM presented a higher
cumulative rate of MACE compared with the ND
group, which was consistently higher among ITD com-
pared with NITD. As previously reported, diabetics
presented also a higher rate of acute and subacute ST
compared with the ND counterpart (1.5% vs. 0.7%,
P< 0.001), which was principally owing to ITD in
patients with DM and significantly associated in each
of the three patient groups with premature (within 30
days) DAPT discontinuation. However, it is noteworthy
that DAPT compliance in our study was significantly
higher than that previously reported [8,9].
Clinical results after PCI with first-generation SES
have been reported in many large randomized con-
trolled trials, clinical registries, and small single-center
series (Table III, Supporting Information Appendix)
[10–13]. Our data confirm the safety and efficacy of
PCI using first-generation SES, extending previous
observations in a very large consecutive and unselected
cohort of DM patients. The Drug-Eluting Sten-
t.DEutschland (DES.DE) registry enrolled 1,526 dia-
betic patients undergoing PCI with either first-
generation SES or paclitaxel-eluting stents at 98 sites
[14]. In the SES group, 1-year mortality and MI rates
were 5.8% and 4.2%, respectively, with an overall tar-
get vessel revascularization (TVR) rate of 12% [14].
Similarly to our data, ITD in the DES.DE registry had
higher rates of overall death (7.4% vs. 4.6%), TVR
(15.1% vs. 10.4%), and ST (6.5% vs. 4.1%) [15]. How-
ever, the overall ST rate was markedly higher than that
observed in our analysis. To this regard, our data pro-
vide an important piece of evidence concerning the
“real-world” risk of ST after first-generation SES im-
plantation when DAPT compliance in daily clinical
practice is high. Indeed, this risk was lower than that
historically reported [16,17] but similar to what has
been shown by other more recent clinical registries
[13,18]. Moreover, our analysis including a large num-
ber of ITD provides strong supporting evidence regard-
ing the interaction between insulin use and long-term
TABLE VI. Rate of Early and Late Stent Thrombosis and Its Relationship to Antiplatelet Regimen at the Time of the Event
0–30 days 31–180 days 181–360 days
DAPT Interrupteda P DAPT Interrupteda P DAPT Interrupteda P
Diabetics 1.0 3.4 0.01 0.41 0.54 0.8 0.12 0.16 0.8
Nondiabetics 0.3 5.3 <0.0001 0.18 0.24 0.8 0.06 0.06 1.0
Values are % of observations.
aDefinitive interruption of one or both antiplatelet agents at the time of stent thrombosis.
TABLE VII. Relationships Between Definite or Probable Stent Thrombosis (ARC Definition) and Cardiac Death, Myocardial In-
farction, Target Vessel Revascularization, and Major Bleeding at 1-Year Follow-up in Diabetics and Nondiabetics
Stent thrombosis
Diabetics
Nondiabetics
(n¼ 65)
Insulin-treated
(n¼ 37)
Non–insulin-treated
(n¼ 33)
Cardiac death 16 (43) 14 (42) 16 (25)
Myocardial infarction 24 (65) 17 (51) 50 (77)
Target vessel revascularization 27 (73) 19 (58) 45 (69)
Major bleeding 0 (0) 0 (0) 2 (3)
Values are number (%) of observations in the corresponding subgroup.
ARC, Academic Research Consortium.
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prognosis after PCI in DM. In the e-SELECT registry,
in addition to higher MACE rate, ITD had a signifi-
cantly shorter event-free survival from Academic
Research Consortium definite ST compared with
NITD, which accounts almost exclusively for the out-
come difference between patients with and without
DM. In the E-Five registry (Table III, Supporting In-
formation Appendix), 12-month outcome data in the
DM subgroup were reported [8]. Interestingly, that
study showed that insulin therapy was not statistically
associated with increased propensity for ST, even
though, similarly to our study, ITD remained at
increased risk of other adverse cardiovascular events.
Understanding the association between insulin therapy
and unfavorable PCI outcomes is challenging. In our
study, as in others, ITD do present a more aggressive
cardiovascular risk profile, including renal failure and
other co-morbidities that may explain the increased
risk of ST and other adverse events. Insulin resistance
has been associated with detrimental biological proc-
esses, such as impaired vascular production of nitric
oxide and increased levels of endothelin-1 and
angiotensin-II [19]. However, insulin therapy per se
may adversely affect cellular proliferation increasing
in-stent restenosis risk and may play a complex role in
promoting ST. Interestingly, although lesion character-
istics between ITD and NITD were similar, the former
experienced a higher TLR rate, which again reinforces
the hypothesis of a different biological milieu in this
patient population.
Bleeding complications carry an ominous prognostic
implication in PCI patients [20,21]. The strong associa-
tion between bleeding and unfavorable outcome is par-
ticularly relevant in acute coronary syndromes because
of multiple factors, including premature DAPT discon-
tinuation, need of transfusion, and background relation-
ship between bleeding propensity and adverse overall
cardiovascular risk profile [22–25]. In our study, the
ongoing major bleeding risk during follow-up was sub-
stantially lower than that previously reported and was
not significantly different among groups [26]. These
results are similar to those of other recent DES regis-
tries in diabetics and do reassure regarding the ongoing
bleeding risk in these patients treated with DAPT up to
1 year after PCI [4,14].
The complex interplay linking DM to unfavorable
PCI results includes altered inflammatory pathways,
endothelial dysfunction, aggressive thrombogenesis,
and monocyte activation, leading to foam cell transfor-
mation and altered smooth muscle cell migration
[27,28]. These mechanisms not only are implicated in
the progression of clinically significant coronary artery
disease but may also jeopardize long-term PCI results
[29–31]. Accordingly, concerns have been raised
regarding PCI in DM patients, especially in case of
multivessel disease, which prompted extensive research
exploring the potential superiority of surgical revascu-
larization [32]. Although randomized controlled trials
suggested a competitive efficacy of bypass surgery
over PCI in diabetics with complex multivessel dis-
ease, it is routine practice worldwide to refer these
patients to the catheterization laboratory in a signifi-
cant proportion of cases [33]. The advent of the DES
era led to improved results among diabetics, thereby
narrowing the outcome gap with surgical revasculariza-
tion [34,35]. However, recent randomized, controlled
trials, such as the Coronary Artery Revascularization in
Diabetes (CARDia) trial, the Synergy between PCI
with Taxus and cardiac surgery (SYNTAX) trial, and
the Future Revascularization Evaluation in patients
with Diabetes Mellitus (FREEDOM) trial, did demon-
strate long-term superiority of coronary bypass over
PCI, mainly driven by a lower TLR rate, particularly
in patients with highly complex lesions [36–38]. One
major limitation of any randomized controlled trial
comparing surgery with PCI is the presence of multiple
exclusion criteria that reduces the external validity of
trial-related findings. For example, in the FREEDOM
trial, patients with congestive heart failure (NYHA
class III or IV), prior cardiac valve surgery, recent (<6
months) PCI, prior stroke, acute ST-elevation MI, and
left main stenosis> 50% were excluded [39]. Accord-
ingly, our data have additive value because they are
able to provide insights of PCI efficacy in a “real-
world” scenario, which may help clinicians in daily
clinical practice to choose differential therapeutic strat-
egies in DM patients with coronary artery disease.
Finally, the field of PCI is rapidly evolving, and
first-generation DES have been overtaken by second-
generation DES, which are expected to be replaced, at
least in specific subsets of patients, by third-generation
devices (bioresorbable-polymer-coated or fully biore-
sorbable DES) [40]. However, it is noteworthy that
direct comparison of a zotarolimus-eluting stent
(Endeavor, Medtronic, Minneapolis, MN) with the
Cypher stent in the Danish Organization for Random-
ized Trials with Clinical Outcome (SORT OUT) III
trial (Table III, Supporting Information Appendix)
showed that treatment with the Endeavor stent com-
pared with the Cypher stent was associated with higher
MACE rate, including TVR and TLR in both diabetics
and ND, with a greater magnitude of differential effect
in the DM group [41]. Comparing our outcome data
with the E-Five Registry that enrolled all-comer PCI
patients treated with the Endeavor stent [8], we can
indirectly extend the SORT OUT III trial data in a
real-world population, given that the overall MACE
rate in the E-Five registry was consistently higher than
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that observed in our population (overall mortality 4.0%
vs. 2.5% and TLR rate 5.3% vs. 2.8%; Table III, Sup-
porting Information Appendix). Recently, the Resolute
zotarolimus-eluting stent (Medtronic) received the FDA
labeling for DM patients on the basis of a prespecified
performance goal (target vessel failure< 14.5%) at 12
months in diabetics [42]. Interestingly, the prespecified
target vessel failure end point (including cardiac death,
vessel-related MI, and ischemia driven revasculariza-
tion) was reported in 7.8% of the 878 diabetic patients
[42]. In our study, a similar outcome of cardiac death,
TLR, and MI occurred in 322 (7.0%) of the 4,577 DM
patients. Overall, the presence of DM seems to limit
the improved comparative effectiveness of second-
generation DES over first-generation DES generally
observed in ND. Accordingly, we believe that our data
may serve as a benchmark for future revascularization
strategies in DM patients with or without the need for
insulin therapy.
Limitations
This study is limited by the fact that the Cypher
stent has been withdrawn from the market in most
countries. However, SES are still used in several cen-
ters worldwide, and our data may help designing future
studies in diabetics. Because we monitored the source
data collected in a random sample representing 20% of
enrolled patients, underreporting of adverse events
remains a potential limitation.
Patients were included only after successful SES im-
plantation and if they did not have contraindications to
prolonged DAPT. This may affect generalizability of
our findings for specific patient subgroups. No infor-
mation was available on efficacy of diabetic treatment,
measured by HbA1c levels, and the severity of DM
was estimated by insulin requirement only. Finally,
follow-up was 1 year only. Thus, it is possible that
the relative ST and MACE risk may have changed
with a longer follow-up, particularly after DAPT dis-
continuation.
Intravascular ultrasound was less commonly used in
DM patients compared with ND, and this may have
had a role in promoting increased propensity to ST in
diabetics.
Insulin requirement does not segregate type 1 and
type 2 DM patients. However, in our study, the number
of patients with type 1 DM was not large, making the
assessment of differential outcomes in these two patho-
physiologically different DM subgroups challenging. In
addition, insulin requirement may serve as a clinical
benchmark of a more aggressive metabolic derange-
ment, and it is useful in clinical practice to stratify dia-
betic patients.
CONCLUSIONS
Treatment with SES in the e-SELECT registry was
associated with an acceptably low rate of MACE in a
large cohort of unselected real-world patients with
DM. However, ST was significantly more frequent as
compared with ND, and this difference was mainly
driven by ITD.
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